Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy.

International forum of allergy & rhinology - 1 Dec 2023

Tervo Jeremy P, DiMango Emily, Gudis David A, Keating Claire, Zhang Yuan, Leu Cheng-Shiun, Altman Kimberly, Vilarello Brandon, Jacobson Patricia, Overdevest Jonathan B

Abstract excerpt

BACKGROUND: Triple-combination therapy of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to reduce morbidity and mortality in people with cystic fibrosis (PwCF). Although patient body mass index (BMI) favorably increases with ETI treatment, factors contributing to this improvement are poorly characterized. Olfaction contributes to appetite stimulation and anticipation of eating, where higher rates of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Olfaction Disorders

Share to Quality of Life

Source

Identifiers

PMID: 37301999
DOI: 10.1002/alr.23209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy.PMID 37301999Read ↗

Systematic review of nasal endoscopy scores in cystic fibrosis patients treated with CFTR modulatorsSemantic proximity Read ↗

A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation.Semantic proximity Read ↗

Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor/tezacaftor/ivacaftor in adults with CF.Semantic proximity Read ↗

Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.Semantic proximity Read ↗

Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.Semantic proximity Read ↗

Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.Semantic proximity Read ↗

Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis.Semantic proximity Read ↗

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.Semantic proximity Read ↗

Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.Semantic proximity Read ↗

Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review.Semantic proximity Read ↗

Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.